PMID- 34481963
OWN - NLM
STAT- MEDLINE
DCOM- 20211209
LR  - 20211214
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
VI  - 47
IP  - 5
DP  - 2021 Sep
TI  - Canagliflozin could improve the levels of renal oxygenation in newly diagnosed 
      type 2 diabetes patients with normal renal function.
PG  - 101274
LID - S1262-3636(21)00057-4 [pii]
LID - 10.1016/j.diabet.2021.101274 [doi]
AB  - OBJECTIVE: To evaluate the effects of canagliflozin on the renal oxygen level and 
      blood perfusion in newly diagnosed type 2 diabetes mellitus (T2DM) patients with 
      normal renal function. METHODS: We conducted a prospective, randomised, and 
      drug-controlled trial to determine the reno-protective effect exerted by 
      canagliflozin in newly diagnosed T2DM patients with normal renal function using 
      blood oxygen level-dependent magnetic resonance imaging (BOLD-MRI) and arterial 
      spin labelling MRI (ASL-MRI). This provides an experimental basis for a 
      first-line of defence for the prevention of diabetic nephropathy. RESULTS: 
      Canagliflozin induced a significant decrease in body weight and diastolic blood 
      pressure compared with glimepiride (all p < 0.05). The high baseline mean 
      estimated glomerular filtration rate (eGFR) in both groups was indicative of a 
      GFR level at a relatively high status that was significantly alleviated after 24 
      weeks of canagliflozin treatment (change from baseline, p = 0.04, and change 
      versus glimepiride control, p = 0.048). However, neither drug regimen 
      significantly affected renal blood perfusion. The R2* values were inversely 
      proportional to the tissue oxygen content. Compared to the baseline, 24 weeks of 
      canagliflozin treatment decreased the R2* values of the renal cortex and medulla 
      by 22.3% (p = 0.005) and 29.2% (p = 0.0002) respectively, and these decreases 
      were significantly greater than in the glimepiride control group (p = 0.0004 and 
      p = 0.02). CONCLUSIONS: Canagliflozin improved the levels of renal oxygenation in 
      newly diagnosed T2DM patients with normal renal function independent of changes 
      in renal blood perfusion.
CI  - Published by Elsevier Masson SAS.
FAU - Zhou, Saijun
AU  - Zhou S
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Tianjin 300134, China.
FAU - Zhang, YuLing
AU  - Zhang Y
AD  - The first centre Hospital of Tianjin, Tianjin 300192,China.
FAU - Wang, TongDan
AU  - Wang T
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Tianjin 300134, China.
FAU - Huang, Shuai
AU  - Huang S
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Tianjin 300134, China.
FAU - Gong, Siyi
AU  - Gong S
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Tianjin 300134, China.
FAU - Wang, Junmei
AU  - Wang J
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Tianjin 300134, China.
FAU - Yu, Pei
AU  - Yu P
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Tianjin 300134, China. Electronic 
      address: peiyu@tmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20210903
PL  - France
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Canagliflozin/*therapeutic use
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Kidney/diagnostic imaging/physiology
MH  - Oxygen
MH  - Oxygen Saturation
MH  - Pharmaceutical Preparations
MH  - Prospective Studies
MH  - Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
OTO - NOTNLM
OT  - Arterial spin labelling magnetic resonance imaging (ASL-MRI)
OT  - Blood oxygen level-dependent MRI (BOLD-MRI)
OT  - Canagliflozin
OT  - Diabetic kidney disease
OT  - Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
OT  - Type 2 diabetes
COIS- Disclosure of interest The authors declare that they have no competing interest.
EDAT- 2021/09/06 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/09/05 20:38
PHST- 2020/12/25 00:00 [received]
PHST- 2021/08/03 00:00 [revised]
PHST- 2021/08/04 00:00 [accepted]
PHST- 2021/09/06 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/09/05 20:38 [entrez]
AID - S1262-3636(21)00057-4 [pii]
AID - 10.1016/j.diabet.2021.101274 [doi]
PST - ppublish
SO  - Diabetes Metab. 2021 Sep;47(5):101274. doi: 10.1016/j.diabet.2021.101274. Epub 
      2021 Sep 3.